Accessibility Menu
Arrow-Thin-Down
S&P 500
6,795.99
+0.8%
+55.97
Arrow-Thin-Down
DJI
47,740.80
+0.5%
+239.25
Arrow-Thin-Down
NASDAQ
22,695.95
+1.4%
+308.27
Arrow-Thin-Down
Bitcoin
$70,668.00
+4.3%
+$2,913.41
Arrow-Thin-Down
AMZN
$213.63
+0.2%
+$0.42
Arrow-Thin-Down
GOOG
$306.36
+2.8%
+$8.27
Arrow-Thin-Down
META
$647.39
+0.4%
+$2.53
Arrow-Thin-Down
MSFT
$409.67
+0.2%
+$0.71
Arrow-Thin-Down
NVDA
$182.64
+2.7%
+$4.82
Arrow-Thin-Down
TSLA
$398.82
+0.5%
+$2.09
Most Active StocksDaily Stock GainersDaily Stock Losers

Where Does Hims & Hers Stock Go From Here?

Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?

By Travis Hoium – Oct 12, 2024 at 8:15AM EST

Hims & Hers (HIMS +40.50%) stock has been on a roller coaster about the availability of GLP-1s to its customers. However, the focus on one treatment may miss the company's strategy. In this video, Travis Hoium shows why Hims & Hers will be fine with or without GLP-1s.

*Stock prices used were end-of-day prices of Oct. 7, 2024. The video was published on Oct. 8, 2024.

Read Next

About the Author

Travis Hoium
Travis Hoium is a contributing Motley Fool stock market analyst covering solar energy, technology, and growth stocks. Before The Motley Fool, Travis was a mechanical engineer at 3M and founded a virtual reality company. He holds a bachelor’s degree in mechanical engineering and a master’s degree in business administration from the University of Minnesota.
TMFFlushDraw
X@travishoium

Travis Hoium has positions in Hims & Hers Health. The Motley Fool recommends CVS Health. The Motley Fool has a disclosure policy. Travis Hoium is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

Stocks Mentioned

Hims & Hers Health Stock Quote
Hims & Hers Health
NYSE: HIMS
$22.12
(+40.50%)+$6.38
CVS Health Stock Quote
CVS Health
NYSE: CVS
$78.26
(+0.44%)+$0.34

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services